DNER and breast cancer: Addressing of therapy resistance has also entailed targeting FBW7 in multiple cancers, including BC.36, 37 Resistance to the BET inhibitors JQ1 and OTX‐015 was documented in T‐ALL tumour cells with FBW7 mutations.13